Wei-Li Kuan

List of Publications by Year
in descending order

27 papers	1,101 citations	516710 16 h-index	526287 27 g-index
29 all docs	29 docs citations	29 times ranked	2032 citing authors

#	Article	IF	Citations
1	Therapeutic Potential of Astrocyte Transplantation. Cell Transplantation, 2022, 31, 096368972211054.	2.5	13
2	Systemic Î±-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinsonâ€™s disease. Molecular Psychiatry, 2021, 26, 556-567.	7.9	24
3	Transvascular delivery of Î±-synuclein preformed fibrils, using the RVG9R delivery system, generates Î±-synuclein pathology in the duodenal myenteric plexus of non-transgenic rats. Molecular Psychiatry, 2021, 26, 365-365.	7.9	1
4	Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks. American Journal of Physiology - Cell Physiology, 2021, 320, C1141-C1152.	4.6	9
5	GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. Nature Communications, 2021, 12, 6666.	12.8	42
6	DJ-1 can form Î²-sheet structured aggregates that co-localize with pathological amyloid deposits. Neurobiology of Disease, 2020, 134, 104629.	4.4	13
7	Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease. Chemical Science, 2020, 11, 525-533.	7.4	35
8	A blueprint for translational regenerative medicine. Science Translational Medicine, 2020, 12, .	12.4	24
9	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2020, 87, 473-488.	4.1	58
10	A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein. Chemical Science, 2020, 11, 4773-4778.	7.4	16
11	Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntingtonâ€™s disease (Enroll-HD). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 622-630.	1.9	18
12	Dermal fibroblasts from patients with Parkinsonâ€™s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. F1000Research, 2017, 6, 1751.	1.6	8
13	Î±-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function. Experimental Neurology, 2016, 285, 72-81.	4.1	51
14	Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system. European Journal of Neuroscience, 2016, 44, 2396-2403.	2.6	12
15	The human cytomegalovirus non-coding Beta2.7 RNA as a novel therapeutic for Parkinson's disease â€“ Translational research with no translation. Virus Research, 2016, 212, 64-69.	2.2	11
16	Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics. ACS Nano, 2016, 10, 307-316.	14.6	84
17	Cerebrovascular and bloodâ€“brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. Annals of Neurology, 2015, 78, 160-177.	5.3	204
18	Modelling the natural history of Huntington's disease progression. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1143-1149.	1.9	15

#	Article	IF	Citations
19	Gold nanoparticles explore cells: Cellular uptake and their use as intracellular probes. Methods, 2014, 68, 354-363.	3.8	62
20	Intracellular SERS Nanoprobes For Distinction Of Different Neuronal Cell Types. Nano Letters, 2013, 13, 2463-2470.	9.1	140
21	A novel neuroprotective therapy for Parkinsonâ€™s disease using a viral noncoding RNA that protects mitochondrial Complex I activity. Journal of Experimental Medicine, 2012, 209, 1-10.	8.5	105
22	Graft-Induced Dyskinesias in Parkinson's Disease: What Is It All About?. Cell Stem Cell, 2010, 7, 148-149.	11.1	32
23	The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinsonâ€™s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology, 2008, 197, 279-293.	3.1	40
24	The future of cell therapies in the treatment of Parkinson's disease. Expert Opinion on Biological Therapy, 2007, 7, 1487-1498.	3.1	17
25	The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiology of Disease, 2007, 25, 594-608.	4.4	33
26	Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease. Xenotransplantation, 2006, 13, 233-247.	2.8	11
27	New Therapeutic Approaches to Parkinsonâ€™s Disease Including Neural Transplants. Neurorehabilitation and Neural Repair, 2005, 19, 155-181.	2.9	21